The aim of this project is to determine the mechanism for entry of the anti-cancer drug cis-diamminedichloroplatinum II (cisplatin) into cancer cells, and how this entry is affected in drug-resistant cells. Drug-sensitive and drug-resistant liver carcinoma cells were incubated for different times (0.5 hr, 1 hr, 2 hr, 4 hr) with 400 micromolar cisplatin and 100 micrograms/ml ferric chloride. Cells were pelleted and rapidly frozen in liquid ethane but high quality cryosectioning was difficult to achieve resulting in a very low yield of usable cryosections. It was therefore necessary to improve the cryosectioning technique by following each step of the preparation using a cryo-electron microscope. Suitable specimens were transferred into an analytical scanning transmission electron microscope (STEM), freeze-dried, imaged at low dose and then analyzed by energy- dispersive x-ray spectroscopy. Spectra were recorded from different organelles including mitochondria, nuclei and endosomes. Elements were quantified using reference spectra and multiple linear least squares fitting. Treatment with 400 micromolar cisplatin for 0.5 hr was found to destroy the Na+/K+ gradient in sensitive cells but not in resistant cells. Measurements indicated that sensitive cells contained organelles with elevated iron levels (approx. 20 mmol/kg dry wt.) and that lower amounts of platinum (approx. 1 mmol/kg dry wt.) were co- localized in some of these compartments. Results suggest that the iron-containing organelles may be endosomes which also take up cisplatin. Resistant cells appeared to be deficient in organelles containing iron or platinum. This is a continuation of Intramural Research Project Z01-RR-10491-01 BEI.

Agency
National Institute of Health (NIH)
Institute
Office of The Director, National Institutes of Health (OD)
Type
Intramural Research (Z01)
Project #
1Z01OD010491-01
Application #
6112715
Study Section
Special Emphasis Panel (BE)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Office of the Director, National Institutes of Health
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Licht, T; Goldenberg, S K; Vieira, W D et al. (2000) Drug selection of MDR1-transduced hematopoietic cells ex vivo increases transgene expression and chemoresistance in reconstituted bone marrow in mice. Gene Ther 7:348-58
Lee, C G; Ramachandra, M; Jeang, K T et al. (2000) Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J 14:516-22
Shen, D W; Goldenberg, S; Pastan, I et al. (2000) Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol 183:108-16
Hafkemeyer, P; Licht, T; Pastan, I et al. (2000) Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers. Hum Gene Ther 11:555-65
Booth, C L; Pulaski, L; Gottesman, M M et al. (2000) Analysis of the properties of the N-terminal nucleotide-binding domain of human P-glycoprotein. Biochemistry 39:5518-26
Cowan, K H; Moscow, J A; Huang, H et al. (1999) Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 5:1619-28
Zhou, Y; Gottesman, M M; Pastan, I (1999) Domain exchangeability between the multidrug transporter (MDR1) and phosphatidylcholine flippase (MDR2). Mol Pharmacol 56:997-1004
Ambudkar, S V; Dey, S; Hrycyna, C A et al. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-98
Zhou, Y; Gottesman, M M; Pastan, I (1999) Studies of human MDR1-MDR2 chimeras demonstrate the functional exchangeability of a major transmembrane segment of the multidrug transporter and phosphatidylcholine flippase. Mol Cell Biol 19:1450-9
Dey, S; Hafkemeyer, P; Pastan, I et al. (1999) A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol. Biochemistry 38:6630-9

Showing the most recent 10 out of 16 publications